news
Study Finds Alzheimer's Biomarkers in 56% of Women With Parkinson's
New research shows that 56% of women diagnosed with Parkinson's disease also carry biological markers for Alzheimer's. The overlap points to mixed neuropathology, where amyloid and tau accumulate alongside dopamine neuron loss. For patients and clinicians, it signals that female neurodegeneration rarely follows a single textbook track.
New research shows that 56% of women diagnosed with Parkinson's disease also carry biological markers for Alzheimer's. The overlap points to mixed neuropathology, where amyloid and tau accumulate alongside dopamine neuron loss. For patients and clinicians, it signals that female neurodegeneration rarely follows a single textbook track.
The architecture take
Neurology spent decades sorting neurodegenerative disorders into neat clinical silos. I was completely wrong. I used to think those diagnostic boundaries were reliable. A 56% copathology rate in women reveals that dual pathology is surprisingly common in late-stage disease. Estrogen drop-offs during perimenopause leave female mitochondria vulnerable to metabolic static, which accelerates amyloid and tau aggregation right alongside dopamine depletion. Whenever I read trials on female neurodegeneration, I notice how rarely clinicians test for both conditions early. Treating only the tremors while amyloid plaques quietly accumulate leaves the nervous system with zero baseline capacity to recover. I spent years assuming standard clinical screens caught cross-disease markers early, but most neurologists still treat one symptom cluster at a time. The practical lesson here is aggressive prevention. Protect vascular tone, track fasting insulin closely, and push for comprehensive biomarker panels instead of waiting for symptoms to overlap.